Expression of EGFRvIII and its co-expression with wild-type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma

Ozlem Sherif; Said A. Khelwatty; Izhar Bagwan; Alan M. Seddon; Angus Dalgleish; Satvinder Mudan; Helmout Modjtahedi

doi:10.3892/or.2024.8831

Expression of EGFRvIII and its co-expression with wild-type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma

Ozlem Sherif
, Said A. Khelwatty
, Izhar Bagwan
, Alan M. Seddon
, Angus Dalgleish
, Satvinder Mudan
, Helmout Modjtahedi

Kingston University
Royal Surrey Hospital
City St George's, University of London
The London Clinic

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	172
Journal	Oncology Reports
Volume	52
Issue number	6
Early online date	22 Oct 2024
DOIs	https://doi.org/10.3892/or.2024.8831
Publication status	Published - Dec 2024

Keywords

Cancer studies

Access to Document

10.3892/or.2024.8831

https://doi.org/10.3892/or.2024.8831

Cite this

Sherif, O., Khelwatty, S. A., Bagwan, I., Seddon, A. M., Dalgleish, A., Mudan, S., & Modjtahedi, H. (2024). Expression of EGFRvIII and its co-expression with wild-type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma. Oncology Reports, 52(6), Article 172. https://doi.org/10.3892/or.2024.8831

@article{2365a51431c74d84be893c9fbc3d1072,

title = "Expression of EGFRvIII and its co-expression with wild-type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma",

keywords = "Cancer studies",

author = "Ozlem Sherif and Khelwatty, \{Said A.\} and Izhar Bagwan and Seddon, \{Alan M.\} and Angus Dalgleish and Satvinder Mudan and Helmout Modjtahedi",

year = "2024",

month = dec,

doi = "10.3892/or.2024.8831",

language = "English",

volume = "52",

journal = "Oncology Reports",

issn = "1021-335X",

publisher = "Spandidos Publications",

number = "6",

}

Sherif, O, Khelwatty, SA, Bagwan, I, Seddon, AM, Dalgleish, A, Mudan, S & Modjtahedi, H 2024, 'Expression of EGFRvIII and its co-expression with wild-type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma', Oncology Reports, vol. 52, no. 6, 172. https://doi.org/10.3892/or.2024.8831

Expression of EGFRvIII and its co-expression with wild-type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma. / Sherif, Ozlem; Khelwatty, Said A.; Bagwan, Izhar et al.
In: Oncology Reports, Vol. 52, No. 6, 172, 12.2024.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Expression of EGFRvIII and its co-expression with wild-type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma

AU - Sherif, Ozlem

AU - Khelwatty, Said A.

AU - Bagwan, Izhar

AU - Seddon, Alan M.

AU - Dalgleish, Angus

AU - Mudan, Satvinder

AU - Modjtahedi, Helmout

PY - 2024/12

Y1 - 2024/12

KW - Cancer studies

U2 - 10.3892/or.2024.8831

DO - 10.3892/or.2024.8831

M3 - Article

SN - 1021-335X

VL - 52

JO - Oncology Reports

JF - Oncology Reports

IS - 6

M1 - 172

ER -